Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Biotechnology

Healthcare
$33.11 -1.81%

-$0.61 today

Market cap
$1.94B
Beta
0.97
P/E (TTM)
13.2
EPS (TTM)
$2.52
52W Low $25.52High $40.87

Volume 0.57M

Average 0.82M

HRMY Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables turns negative

Q2 FY2026 accounts payables was -$6.92M, compared with $10.84M a year earlier. Trailing-twelve-month accounts payables was -$4.66M.

Context

  • Accounts payables amounted to 0.5% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near -$6.92M or moves back toward the trailing-twelve-month quarterly average of -$1.16M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$6.92M-163.4% QoQ
Last fiscal yearDec 2025
$3.95M+173.3% YoY
LTMJun 2026
-$4.66M-133.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-163.8%——
1 year+173.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
3.95M USD
Year-over-year change
+173.3%

Accounts Payables vs competitors

How HRMY compares with its peers on the latest reported figures

  • HRMY's LTM Jun 2026 accounts payables of $4.66M is the 2nd largest of the 4 companies compared; the peer median is $1.81M.
  • Its year-over-year change of -133.1% is the lowest of 2, against a peer median of +305.3%.
  • Accounts payables amounts to 0.5% of revenue for HRMY.
HRMY Competitors Peer median
Accounts Payables for HRMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$5.43M ———
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$4.66M -133.1%—0.5%
CMPSCOMPASS Pathways plcLTM Mar 2026$1.81M +305.3%-6.6%—
NERVMinerva Neurosciences, Inc.LTM Jun 2026$423.37K —+6.2%—
APMDApnimed, Inc.—— ———
Peer median (excluding HRMY) $1.81M+305.3%-0.2%—

Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income34.6M181.47M128.85M145.49M158.69M
Depreciation & Amortization18.84M23.39M24.36M24.11M25.34M
Deferred Income Tax00(13.42M)(29.3M)0
Stock-Based Compensation16.11M26.91M31.71M42.6M44.9M
Change in Working Capital2.19M(6.89M)35.04M(7.32M)91.82M
Accounts Receivables(12.67M)(19.9M)(19.4M)(8.89M)(13.75M)
Inventory(609K)135K(1.07M)(1.84M)1.84M
Accounts Payables008.95M(5.38M)3.95M
Other Working Capital15.46M12.87M46.55M8.79M99.78M
Other Non-Cash Items26.83M(80.4M)12.85M44.23M27.47M
Operating Cash Flow98.56M144.47M219.39M219.82M348.2M
Capital Expenditures(298K)(172K)(312K)(1.15M)(310K)
Acquisitions (Net)00(36.97M)(33.07M)0
Purchases of Investments00(127.47M)(105.29M)(86.15M)
Sales of Investments00118.31M98.53M81.06M
Other Investing Activities(100M)(141.66M)0(26.5M)(15M)
Investing Cash Flow(100.3M)(141.83M)(46.44M)(67.48M)(39.65M)
Debt Repayment(500K)(2M)(1.25M)(15M)(16.25M)
Common Stock Issued0006.5M10.21M
Common Stock Repurchased00(100M)00
Dividends Paid00000
Other Financing Activities7.92M8.84M(3.79M)(2.5M)(3M)
Financing Cash Flow7.42M6.84M(105.55M)(11M)(9.05M)
Effect of Forex Changes00000
Net Change in Cash5.68M9.48M67.4M141.34M299.5M
Free Cash Flow98.26M144.29M219.08M218.67M347.89M

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Intrinsic Alpha fair value

Locked

Current Price

$33.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.